KLRK1 and neoplasm: Increased tumor sensitivity to NK cells has been observed after treatment with proteasome inhibitors, doxorubicin or histone deacetylase inhibitors that upregulates the expression of NKG2D ligands, the secretion of proinflammatory cytokines, or the expression of TNF receptors.